Zhang YX, Hu HS, Sun BQ. Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients. World J Cardiol 2024; 16(10): 611-615 [PMID: 39492970 DOI: 10.4330/wjc.v16.i10.611]
Corresponding Author of This Article
Bao-Qing Sun, PhD, Professor, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, No. 28 Qiaozhong Middle Road, Guangzhou 510120, Guangdong Province, China. sunbaoqing@vip.163.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Oct 26, 2024; 16(10): 611-615 Published online Oct 26, 2024. doi: 10.4330/wjc.v16.i10.611
Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients
Yan-Xi Zhang, Hai-Sheng Hu, Bao-Qing Sun
Yan-Xi Zhang, Hai-Sheng Hu, Bao-Qing Sun, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou 510120, Guangdong Province, China
Co-first authors: Yan-Xi Zhang and Hai-Sheng Hu.
Author contributions: Zhang YX and Hu HS contributed equally to this work; Sun BQ designed the overall concept and outline of the manuscript; Hu HS contributed to the discussion and design of the manuscript; Zhang YX contributed to the writing and editing of the manuscript and illustrations; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bao-Qing Sun, PhD, Professor, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, No. 28 Qiaozhong Middle Road, Guangzhou 510120, Guangdong Province, China. sunbaoqing@vip.163.com
Received: August 16, 2024 Revised: September 29, 2024 Accepted: October 11, 2024 Published online: October 26, 2024 Processing time: 62 Days and 3.1 Hours
Abstract
We comment on an article by Grubić Rotkvić et al published in the recent issue of the World Journal of Cardiology. We specifically focused on possible factors affecting the therapeutic effectiveness of sodium-dependent glucose transporter inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and their impact on comorbidities. SGLT2i inhibits SGLT2 in the proximal tubules of the kidneys, lowering blood glucose levels by inhibiting glucose reabsorption by the kidneys and causing excess glucose to be excreted in the urine. Previous studies have demonstrated a role of SGLT2i in cardiovascular function in patients with diabetes who take metformin but still have poor glycemic control. In addition, SGLT2i has been shown to be effective in anti-apoptosis, weight loss, and cardiovascular protection. Accordingly, it is feasible to treat patients with T2DM with cardiovascular or renal diseases using SGLT2i.
Core Tip: Studies have revealed that type 2 diabetes mellitus (T2DM) patients often suffer from multiple comorbidities that can be effectively treated with sodium-dependent glucose transporter inhibitors (SGLT2i), which has been linked to their anti-apoptotic properties, promotion of weight loss, and cardiovascular protection. Correctly avoiding the risks of SGLT2i use and aggressive use of the drug in patients with T2DM and its complications to alleviate symptoms are feasible.
